Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2Thoracic 1Head & Neck 1Endocrine 1Breast 1

Conditions

Neuroendocrine Tumors 394Multiple Endocrine Neoplasia Type 1 156Carcinoma, Neuroendocrine 123Thyroid Cancer, Papillary 118Pituitary Neoplasms 114Thyroid Neoplasms 100Pheochromocytoma 91Neoplasms 79Carcinoid Tumor 76Thyroid Carcinoma, Anaplastic 73Adrenocortical Carcinoma 73Paraganglioma 65Neoplasm Metastasis 56Adenocarcinoma, Follicular 53Carcinoma, Non-Small-Cell Lung 51Carcinoma, Medullary 50Insulinoma 49Pancreatic Neoplasms 47Adenoma, Islet Cell 47Colorectal Neoplasms 44Breast Neoplasms 44Small Cell Lung Carcinoma 42Sarcoma 42Gastro-enteropancreatic neuroendocrine tumor 42Carcinoma, Renal Cell 41Somatostatinoma 38Head and Neck Neoplasms 38Melanoma 37Lung Neoplasms 37Adrenal Gland Neoplasms 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Substance-Related Disorders × Endocrine × Clear all
NCT02358226 2020-02-17

HIV & Drug Abuse Prevention for South African Men

University of California, Los Angeles

Phase 3 Completed
1,211 enrolled
Endocrine

Acquired Immunodeficiency Syndrome, Alcoholism, Multiple Endocrine Neoplasia Type 1, Substance-Related Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡